How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

853 results for

Antithyroid Drug

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Elevated Serum IL-17 Expression at Cessation Associated with Graves' Disease Relapse (PubMed)

Elevated Serum IL-17 Expression at Cessation Associated with Graves' Disease Relapse Antithyroid drug (ATD) treatment occupies the cornerstone therapeutic modality of Graves' disease (GD) with a high relapse rate after discontinuation. This study aimed to assess potential risk factors for GD relapse especially serum interleukin-17 (IL-17) expression.Consecutive newly diagnosed GD patients who were scheduled to undergo ATD therapy from May 2011 to May 2014 were prospectively enrolled. Risk

Full Text available with Trip Pro

2018 International journal of endocrinology

182. Incidence of neonatal hyperthyroidism among newborns of Graves' disease patients treated with radioiodine therapy. (PubMed)

of NH among newborns of mothers who conceived within two years after RAI therapy, and to identify predictors of NH.GD patients (n = 145) who conceived within two years after RAI therapy were retrospectively reviewed, and information regarding their newborns was collected.Of the 145 pregnant women, 54 (37%) were treated with antithyroid drugs or potassium iodide for maternal hyperthyroidism during the first trimester. There were eight newborns with NH, resulting in an incidence of 5.5%. Seven (...) of the eight mothers whose newborns had NH were treated with antithyroid drugs or potassium iodide during their pregnancy. The incidence of NH among the newborns of mothers who conceived within 6-12 months after RAI therapy was 8.8%, within 12-18 months was 5.5%, and within 18-24 months was 3.6%. Multivariate analysis revealed that the TRAb values in the third trimester were the only risk factor for NH. The cutoff TRAb value in the third trimester for predicting NH was 9.7 IU/L (reference value <2.0 IU/L

2018 Thyroid

183. Radiofrequency Ablation for Amiodarone-induced Thyrotoxicosis

not normalized their thyroid levels after one month of standard therapy or Have persistent and clinically significant thyrotoxicosis (less than 25% decrease in T4 value or patients requiring hospitalization with CHF, tachyarrhythmias, hemodynamic instability or similar co-morbidities) after 2 weeks of standard therapy where additional medical therapy is deemed unlikely to be beneficial or with high risk of side-effects (e.g. hepatotoxicity of antithyroid medications, agranulocytosis of potassium perchlorate (...) or ATD or fluid retention associated with steroids). Exclusion Criteria: Pregnancy Patients with prior neck surgery or neck radiation Patients with neck anatomy that precludes easy access by RFA to the entirety of thyroid parenchyma Patients on anticoagulation therapy Patients with comorbidities deemed too high of a risk for general anesthesia Treatment with another investigational drug or intervention (within 6 weeks of planned RFA). Current drug or alcohol use or dependence that, in the opinion

2018 Clinical Trials

184. Preoperative thyroid function and weight loss after bariatric surgery. (PubMed)

hormone or antithyroid drugs and those with preoperative evaluation consistent with overt hypothyroidism or hyperthyroidism were excluded. The preoperative levels of TSH and FT4 were not associated with weight loss after bariatric surgery. The variation of FT3 within the reference range was also not associated with weight loss. In contrast, the subgroup with FT3 above the reference range (12.3% of patients) had a significantly higher excess weight loss than patients with normal FT3. This difference

2018 International Journal of Obesity

185. Hyperthyroidism. (PubMed)

thyroid hormones. Treatment options for Graves' disease include antithyroid drugs, radioactive iodine therapy, and surgery, whereas antithyroid drugs are not generally used long term in toxic nodular goitre, because of the high relapse rate of thyrotoxicosis after discontinuation. β blockers are used in symptomatic thyrotoxicosis, and might be the only treatment needed for thyrotoxicosis not caused by excessive production and release of the thyroid hormones. Thyroid storm and hyperthyroidism (...) Hyperthyroidism. Hyperthyroidism is characterised by increased thyroid hormone synthesis and secretion from the thyroid gland, whereas thyrotoxicosis refers to the clinical syndrome of excess circulating thyroid hormones, irrespective of the source. The most common cause of hyperthyroidism is Graves' disease, followed by toxic nodular goitre. Other important causes of thyrotoxicosis include thyroiditis, iodine-induced and drug-induced thyroid dysfunction, and factitious ingestion of excess

Full Text available with Trip Pro

2016 Lancet

186. Effect of Goiter Dispersion Formula on Serum Cytokines in Hyperthyroidism Patients with Neurologic Manifestations of Graves' Disease: A Randomized Trial on 80 Cases. (PubMed)

Effect of Goiter Dispersion Formula on Serum Cytokines in Hyperthyroidism Patients with Neurologic Manifestations of Graves' Disease: A Randomized Trial on 80 Cases. This study is aimed to explore the combined use of goiter dispersion formula and antithyroid drugs in the treatment of patients with neurologic manifestations of Graves' disease by examining its modulating effects on patients' cytokines.A total of 80 patients with Graves' disease were randomly divided into treatment and control (...) groups. Patients of the treatment group received goiter dispersion formula and antithyroid drugs (methimazole or propylthiouracil), whereas those of the control group received antithyroid drug alone. FT3, FT4, and TSH contents were detected by chemiluminescence immunoassay at pre- and post-treatment; interleukin (IL)-2, IL-8, and IL-17 serum levels before and after the treatment were detected by radioimmunoassay; thyroid B-mode ultrasound and liver and renal function tests were performed in all

2018 Journal of Alternative and Complementary Medicine Controlled trial quality: uncertain

187. Thyroid Cancer Treatment (PDQ®): Patient Version

are not cancer. Your doctor may find a lump ( ) in your thyroid during a routine medical exam. A thyroid nodule is an growth of thyroid in the thyroid. Nodules may be solid or -filled. When a thyroid nodule is found, an of the thyroid and a are often done to check for of . to check thyroid hormone levels and for antithyroid in the may also be done to check for other types of thyroid disease. Thyroid nodules usually don't cause or need treatment. Sometimes the thyroid nodules become large enough (...) of thyroid hormone and controls how fast follicular thyroid cells grow. The blood may also be checked for high levels of the hormone and antithyroid antibodies. : A procedure in which a blood sample is checked to measure the amounts of certain substances, such as , released into the blood by organs and tissues in the body. An unusual (higher or lower than normal) amount of a substance can be a sign of disease. Ultrasound exam : A procedure in which high-energy sound waves (ultrasound) are bounced off

2016 PDQ - NCI's Comprehensive Cancer Database

188. Alopecia, androgenetic - female

, and scarring of hair follicles may occur. See the CKS topic on for more information. Other underlying causes of hair loss include: Hypothyroidism and other endocrine disorders such as hyperprolactinaemia. See the CKS topic on for more information. Iron deficiency and poor nutritional status. Drugs, including those: Implicated in telogen effluvium. With an androgenic effect (such as anabolic steroids or progestogens). With an antithyroid action (such as carbimazole). Other systemic disease (...) diagnosis for the hair loss should be suspected if assessment reveals: Systemic disease, such as a recent severe infection, iron deficiency, or hypothyroidism. Exposure to certain drugs, such as antidepressants, anabolic steroids, progestogens, carbimazole, or chemotherapy. Extreme dietary habits or rapid weight loss. Inflammation, papules or pustules, scaling, or scarring of the scalp. Laboratory testing for the diagnosis of androgenetic alopecia is generally unnecessary. Tests for thyroid function

2016 NICE Clinical Knowledge Summaries

189. Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy

Intervention/treatment Phase Graves Disease Graves Ophthalmopathy Graves' Ophthalmopathy Worsened Drug: Antithyroid Drug Procedure: Total thyroidectomy Phase 3 Detailed Description: Introduction: Graves disease (GD) is characterized by thyrotoxicosis and goiter, arising through circulating autoantibodies that bind to and stimulate the thyroid hormone receptor (TSHR). Graves' ophthalmopathy (GO) is characterized by inflammation, expansion of the extraocular muscles and an increase in retroorbital fat (...) Completion Date : June 1, 2019 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Thyroidectomy Total thyroidectomy Drug: Antithyroid Drug Antithyroid drug Other Names: Thiamazol Propylthiouracil Active Comparator: Antithyroid drug Thiamazol, Propylthiouracil Procedure: Total thyroidectomy Operation Outcome Measures Go to Primary Outcome Measures : Muscle index (MI) from

2017 Clinical Trials

190. The Role of Thyroid Status in Regulating Brown Adipose Tissue Activity, White Adipose Tissue Partitioning and Resting Energy Expenditure

the relationship between brown adipose tissue (BAT) volume/activity, white adipose tissue (WAT) partitioning and basal metabolic rate (BMR) in hyperthyroid patients transitioning to euthyroidism via antithyroid drugs. To compare euthyroid outcomes (BAT, WAT, BMR, body composition, body weight and insulin resistance) achieved by hypothalamus-pituitary-thyroid (HPT) set point vs. normal ranges of plasma free thyroxine 4 (FT4) and throxine stimulating hormone (TSH). Condition or disease Intervention/treatment (...) . Once subjects have consented to participate in this study, they will receive standard antithyroid drug (ATD) therapy as indicated clinically which in current practice will either be carbimazole (CMZ) or thiamazole (TMZ).The clinic endocrinologists at TTSH will be in charge of deciding on the ATD dose required based on the latest FT4, FT3 and TSH blood test results as per standard medical practice. . Subjects will then be scheduled for Visit 2 for baseline research measurements while you are still

2017 Clinical Trials

191. Sialic acid-binding immunoglobulin-like lectin1 as a Novel Predictive Biomarker for Relapse in Graves' Disease -A multicenter study. (PubMed)

in long-term remission after the discontinuation of antithyroid drugs (ATDs). Based on the DNA microarray analysis, we focused on Sialic acid-binding immunoglobulin-like lectin1 (SIGLEC1) as a candidate novel biomarker to predict GD relapse. Three hundred and fifty-eight patients with GD in the thyroid clinics of four different hospitals in Japan were included in a cross-sectional study to establish whether SIGLEC1 mRNA levels distinguish GD relapse experience from long-term remission. An additional

2017 Thyroid

192. THE EFFECTS OF ADEQUATE IODINE SUPPLY ON THE INCIDENCE OF IODINE-INDUCED THYROID DISORDERS IN SLOVENIA. (PubMed)

of patients with overt hyperthyroidism decreased, predominantly due to the increased proportion of patients with subclinical hyperthyroidism (p = 0.007 and p = 0.015, respectively). The duration of treatment with antithyroid drugs and perchlorate was significantly shorter after the increase in iodine supply than it was before (p = 0.001 and p = 0.002, respectively). A significantly positive correlation between the year of the occurrence of excessive iodine intake (EII)-induced thyroid disease

2017 Thyroid

193. Comparative Effectiveness of Treatment Choices for Graves' Hyperthyroidism - A Historical Cohort Study. (PubMed)

profile of radioactive iodine (RAI), antithyroid drugs (ATDs), and thyroidectomy in a tertiary healthcare facility.The cohort included consecutive adults diagnosed with GD from January 2002 to December 2008, who had complete follow-up after treatment at the Mayo Clinic, Rochester, Minnesota. Data on treatment modalities, disease relapses, and adverse effects were extracted manually and electronically from the electronic medical records. Kaplan-Meier analyses were performed to evaluate the association

Full Text available with Trip Pro

2017 Thyroid

194. A rare case of methimazole-induced cholestatic jaundice in an elderly man of Asian ethnicity with hyperthyroidism: A case report. (PubMed)

A rare case of methimazole-induced cholestatic jaundice in an elderly man of Asian ethnicity with hyperthyroidism: A case report. Methimazole is an antithyroid drug that is widely used for the treatment of hyperthyroidism. As an inhibitor of the enzyme thyroperoxidase, methimazole is generally well-tolerated. However, there have been increasing reports of methimazole-induced liver damage, although this effect of methimazole has been limited by the absence of objective diagnosis of the liver

Full Text available with Trip Pro

2017 Medicine

195. Effects of methimazole and propylthiouracil exposure during pregnancy on the risk of neonatal congenital malformations: A meta-analysis. (PubMed)

Effects of methimazole and propylthiouracil exposure during pregnancy on the risk of neonatal congenital malformations: A meta-analysis. The aim of this study was to determine the effect of exposure to different antithyroid drugs during pregnancy on the incidence of neonatal congenital malformations.A meta-analysis was performed to compare the incidence of neonatal congenital malformations after exposure to different antithyroid drugs during pregnancy. Twelve studies that met the inclusion (...) criteria were included in this meta-analysis. PubMed, Embase, and CENTRAL databases were searched from inception until January 2017. Study designs included case-control studies, prospective cohort studies, and retrospective cohort studies.Twelve studies involving 8028 participants with exposure to different antithyroid drugs during pregnancy were included in this study; however, only 10 studies involving 5059 participants involved exposure to different antithyroid drugs exactly during pregnancy. Our

Full Text available with Trip Pro

2017 PloS one

196. Serum 25-hydroxyvitamin D might be an independent prognostic factor for Graves disease recurrence. (PubMed)

Serum 25-hydroxyvitamin D might be an independent prognostic factor for Graves disease recurrence. Graves disease is the most common cause of thyrotoxicosis. Although medical intervention with antithyroid drugs (ATDs) is commonly the first choice of treatment in Korea, the remission rate associated with this approach is not satisfactory. During ATD therapy, low or undetectable serum levels of thyroid-stimulating hormone (TSH) receptor antibodies (TRAbs) have been reported to affect

Full Text available with Trip Pro

2017 Medicine

197. Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: a systematic review. (PubMed)

Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: a systematic review. Patients with chronic spontaneous urticaria (CSU) are widely held to often have other autoimmune disorders, including autoimmune thyroid disease. Here, we systematically evaluated the literature on the prevalence of thyroid autoimmunity in CSU and vice versa. There is a strong link between CSU and elevated levels of IgG antithyroid autoantibodies (AAbs), with most of a large number of studies (...) reporting rates of ≥10%. Levels of IgG against thyroid peroxidase (TPO) are more often elevated in CSU than those of other IgG antithyroid AAbs (strong evidence). Levels of IgG antithyroid AAbs are more often elevated in adult patients with CSU than in children (strong evidence). Patients with CSU exhibit significantly higher levels of IgG antithyroid AAbs (strong evidence) and IgE-anti-TPO (weak evidence) than controls. Elevated IgG antithyroid AAbs in CSU are linked to the use of glucocorticoids (weak

Full Text available with Trip Pro

2017 Allergy

198. MANAGEMENT OF ENDOCRINE DISEASE: Subclinical Thyrotoxicosis: Prevalence, Causes and Choice of Therapy. (PubMed)

of subclinical thyrotoxicosis, and how treatment should be tailored to the specific cause. We advocate radioactive iodine treatment to be the first-line treatment in majority of patients suffering from subclinical thyrotoxicosis due to multinodular toxic goitre and solitary toxic adenoma, but we do generally not recommend it as the first-line treatment in patients suffering from subclinical Graves' hyperthyroidism. Such patients may benefit mostly from antithyroid drug therapy. Subclinical thyrotoxicosis

Full Text available with Trip Pro

2017 European Journal of Endocrinology

199. Arrhythmia and thyroid dysfunction.

hyperthyroidism, subclinical hypothyroidism, levothyroxine, triiodothyronine, antithyroid drugs, radioiodine, deiodinase, atrial flutter, supraventricular arrhythmia, ventricular arrhythmia, ventricular tachycardia, ventricular fibrillation, torsade de pointes, amiodarone and atrial fibrillation. The investigation was restricted to reports published in English.The outcome of this analysis suggests that patients with untreated overt clinical or subclinical thyroid dysfunction are at increased risk

2017 Herz

200. Graves’ disease coexisting with resistance to thyroid hormone: a rare case (PubMed)

Graves’ disease coexisting with resistance to thyroid hormone: a rare case A rare case of resistance to thyroid hormone (RTH) complicated with Graves' hyperthyroidism was reported. The management of this disease is similar to that of Graves' disease. Antithyroid drug therapy is the first choice, and iodine therapy and surgery are not recommended due to the possibility of severe hypothyroidism and enlargement of the pituitary gland.

Full Text available with Trip Pro

2017 Clinical Case Reports

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>